Novo Nordisk says Victoza superior to Amylin rival
COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Monday a study had confirmed its diabetes drug Victoza provided greater reductions in blood sugar levels than rival drug Byetta from Amylin.
Novo Nordisk said in a statement the study, presented at the 72nd Annual Scientific Sessions of the ADA in Philadelphia, showed more patients appeared to favor a drug given by injection over a drug which is given orally.
The study also confirmed weight loss and cost-effectiveness in the use of Victoza, Novo Nordisk said.
(Reporting by Copenhagen Newsroom; Editing by Mark Potter)
- WTO overcomes last minute hitch to reach its first global trade deal
- Colorado baker discriminated by denying gay couple wedding cake: judge
- U.S. freeze shows no sign of weekend melt after deadly storm
- Flights delayed as air pollution hits record in Shanghai
- Australia foreign minister downplays China air defense zone tension in visit
Nelson Mandela: 1918 - 2013
Reuters looks at the life and times of Nelson Mandela, an icon of peace and reconciliation who came to embody the struggle for justice around the world. Video